Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
192
-
Total 13F shares, excl. options
-
36.2M
-
Shares change
-
-877K
-
Total reported value, excl. options
-
$3.57B
-
Value change
-
-$112M
-
Put/Call ratio
-
1.05
-
Number of buys
-
111
-
Number of sells
-
-73
-
Price
-
$98.85
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2017
235 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2017.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 192 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.2M shares
of 49.6M outstanding shares and own 72.85% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (4.36M shares), Vanguard Group Inc (2.62M shares), BlackRock Inc. (2.39M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.22M shares), ORBIMED ADVISORS LLC (2.18M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.98M shares), Partner Fund Management, L.P. (1.82M shares), FMR LLC (1.71M shares), STATE STREET CORP (1.19M shares), and D. E. Shaw & Co., Inc. (947K shares).
This table shows the top 192 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.